Not available in the U.S.
Mechanism of action: Betahistine ballicule
Visual mnemonic: Betahistine mascot
“Bettor hissing”
Legos → theme for H3 antihistamine
What it isH3 antagonist and weak H1 agonist; Meniere disease.
Why this oneIt is standard therapy for Meniere vertigo across Europe and Canada.
What limits itA large randomized trial found no benefit over placebo. Not US-approved.
Molecular structure: Betahistine
FDA-approved for
Off-label
- Meniere disease (approved in Europe and Canada)
Principal riskA large randomized trial found no benefit over placebo
Classes and tags
Clinical profile
Therapeutic safety burden1 / 4
Overdose danger1 / 4
Sedation liability0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4
Open Betahistine in the interactive console ↗